Form 4 for RGNX REGENXBIO Inc.
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-01 · accession 0001562180-22-000159 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-04 | 2022-01-01 | RGNX | PAKOLA STEVE | Chief Medical Off | F - Tax | $32.70 | -1,152 | 9,848 | -10% | -$37.7K |
| D | 2022-01-04 | 2022-01-03 | RGNX | PAKOLA STEVE | Chief Medical Off | A - Grant | $0.00 | +8,900 | 17.1K | +108% | $0 |
| D | 2022-01-04 | 2022-01-03 | RGNX | PAKOLA STEVE | Chief Medical Off | S - Sale | $33.75 | -1,598 | 8,250 | -16% | -$53.9K |
| D | 2022-01-04 | 2022-01-03 | RGNX | PAKOLA STEVE | Chief Medical Off | A - Grant | $0.00 | +42.5K | 42.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-01 | F | D | 1,152 | $32.70 | 9,848 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-03 | A | A | 8,900 | $0.00 | 17,150 | D | — | — | (F3) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. |
| 3 | Common | Common Stock | 2022-01-03 | S | D | 1,598 | $33.75 | 8,250 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-01-03 | A | A | 42,500 | $0.00 | 42,500 | D | $34.31 · — to 2032-01-03 | 42,500 Common Stock | (F4) 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. |